These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26212478)

  • 1. A long war begins: biosimilars versus patented biologics.
    Bocquet F; Paubel P
    J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars: current scientific and regulatory considerations.
    Chugh PK; Roy V
    Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars.
    Ross A; Richard K
    Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI; Fitzpatrick RW; Chapman SR
    Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracking the price of existing biologics when drugs enter the market.
    Stiff KM; Cline A; Feldman SR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):375-377. PubMed ID: 31177860
    [No Abstract]   [Full Text] [Related]  

  • 11. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 13. Iraqi regulatory authority current system and experience with biosimilars.
    Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
    Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars for insulin: a cost-saving alternative?
    McCall C
    Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: Hope and concern.
    Emmanouilides CE; Karampola MI; Beredima M
    J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.